Effect of food on the pharmacokinetics of Olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors.
Rolfo, C Swaisland, H Leunen, K Rutten, A Soetekouw, P Slater, S Verheul, H Fielding, A So, K Bannister, W
Rolfo, C
Swaisland, H
Leunen, K
Rutten, A
Soetekouw, P
Slater, S
Verheul, H
Fielding, A
So, K
Bannister, W
Citations
Altmetric:
Abstract
The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer.
Description
Date
2015-06
Publisher
Collections
Keywords
Type
Article
Citation
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. 2015, 32 (6):510-22 Adv Ther